Renal TransplantationNCT06706154
Exercise Capacity in Kidney Transplant Recipients
An observational study of Renal Transplantation, run by Hacettepe University at 1 site in Turkey (Türkiye).
Trial summary
This study aimed to determine the determinants of 6 minute walk test distance in patients with kidney transplant recipients. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Renal Transplantation
- How many people
- 27 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 17 Aug 2024to May 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with kidney transplantation will be included.
Who may be able to join
- Patients with kidney transplantation
- At least 6 months after the kidney transplant
- Being aged 18-65
- Not having regular exercise habits
- Voluntary participation in the study
Who cannot join
- Having a musculoskeletal problem that may interfere with the tests
- Having neurological impairment
- Having chronic lung disease
- Having had any cardiovascular event in the last 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Hacettepe University
Ankara
Naciye Vardar-Yagli, +90 312 305 15 76 ext. 123, naciyevardar@yahoo.com
About this study
Official title: Determinants of Exercise Capacity in Kidney Transplant Recipients
This study aimed to determine the determinants of 6 minute walk test distance in patients with kidney transplant recipients.
- Conditions
- Renal Transplantation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Kidney transplant recipients | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Exercise capacity
Will be evaluated with 6 minute walk test. After the test, total walking distance will be recorded.
Measured: 1st day
Respiratory function
FEV1, FVC, FEV1/FVC, PEF, FEF25-75 will be measured by lung function test.
Measured: 1st day
Respiratory muscle strength
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured using a mouth pressure device.
Measured: 1st day
Musle function
Knee extensor and hand grip strength will be evaluated with a dynamometer.
Measured: 1st day
Secondary outcomes (1)
Physical activity
Physical activity level will be evaluated using International Physical Activity Questionnaire-Short form. This questionnaire lists activities and asks for estimates of the duration and frequency of each activity in the past week. The durations are multiplied by the MET value for each activity and the results for all items are summed to give an overall physical activity score.
Measured: 1st day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2024
- Study start17 Aug 2024
- Primary completionJan 2025 (estimated)
- Study completionMay 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal TransplantationStudies of the same condition, open and under way.
- More trials run by Hacettepe UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hacettepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Merve Firat, Hacettepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06706154
- Sponsor's protocol ID
- FTREK24/67
- Status last verified
- Nov 2024
- First submitted
- 4 Nov 2024
- Last updated
- 26 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determinants of Exercise Capacity in Kidney Transplant Recipients
- ClinicalTrials.gov ID
- NCT06706154
- Acronym / sponsor ID
- FTREK24/67
- Conditions
- Renal Transplantation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- Hacettepe UniversityUniversity, hospital or other
- Study start
- 17 Aug 2024 (actual)
- Primary completion
- Jan 2025 (estimated)
- Study completion
- May 2025 (estimated)
- First posted
- 26 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to determine the determinants of 6 minute walk test distance in patients with kidney transplant recipients.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Kidney transplant recipients | – | – |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with kidney transplantation will be included.
Key inclusion criteria (5 listed)
- Patients with kidney transplantation
- At least 6 months after the kidney transplant
- Being aged 18-65
- Not having regular exercise habits
- Voluntary participation in the study
Key exclusion criteria (4 listed)
- Having a musculoskeletal problem that may interfere with the tests
- Having neurological impairment
- Having chronic lung disease
- Having had any cardiovascular event in the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Exercise capacity
Time frame: 1st day
Will be evaluated with 6 minute walk test. After the test, total walking distance will be recorded.
Respiratory function
Time frame: 1st day
FEV1, FVC, FEV1/FVC, PEF, FEF25-75 will be measured by lung function test.
Respiratory muscle strength
Time frame: 1st day
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be measured using a mouth pressure device.
Musle function
Time frame: 1st day
Knee extensor and hand grip strength will be evaluated with a dynamometer.
1 secondary outcome
Physical activity
Time frame: 1st day
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2024.
Related trials for Renal Transplantation
Enrolling by invitationPhase 3
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Antibody-mediated Rejection, Microvascular Inflammation
RecruitingPhase 3
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
Cytomegalovirus (CMV), Kidney Transplant; Complications
Not yet recruitingPhase 1
ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications
RecruitingPhase 1
Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease
End Stage Renal Disease
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Transplantation, run by Hacettepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Merve Firat (+90 850 441 02 44, mervefirat@ahievran.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exercise capacity (time frame: 1st day). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2024.